The Global Pneumonia Vaccine Market was valued at $7,083 million in 2017 and is expected to reach $10,215 million by 2025, growing at a CAGR of 5% from 2018 to 2025.
Pneumonia is a disease that causes lung contamination occurring in one or both the lungs caused by bacterial organisms, viruses, or fungi; bacterial pneumonia is the most common in adults. Pneumonia results in irritation around the ‘sacs’ also known as alveoli of the lungs, which causes the alveoli to fill with pus, as a result causing breathing issues. Pneumococcal diseases are most common in younger children; however, adults and elderly population are more prone to pneumococcal contaminations and even death. Pneumonia vaccines are primarily given to the children less than 2 years and adults 65 years and older. In general, vaccines are given at 2,4,6, and 12 thought 15 months old for children; and single dose will be given for the adults aged 65 years and older. These vaccines help providing immunization against 13 types of pneumococcal bacteria that cause infection in the lungs.
Download Sample Report @ https://www.alliedmarketresearch.com/request-sample/2730
Increasing government support in creating awareness regarding pneumonia immunization programs, rising prevalence of pneumococcal contaminations within the population, and introduction of novel pneumococcal vaccines are some of the major factors driving the growth of the global pneumonia vaccine market. However, longer timelines required for production of pneumococcal vaccines and higher costs associated with development of the vaccines are hindering the growth of the market across the globe. Also, developing the protein-based vaccines for pneumonia are anticipated to create opportunities for the expansion of this market during the forecast period.
Global Pneumonia Vaccine Market Segmentation
The global pneumonia vaccine market is segmented based on vaccine type, product type, sector type, distribution channel and region. Based on vaccine type, the market is divided into Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine. Based on product type, the market is categorized into Prevnar 13, Synflorix, and Pneumovax 23. Based on sector type, the market is divided into Public and Private. Based on distribution channel, the market is segmented into Distribution Partner Companies, Non-governmental Organizations (NGO) and Government Authorities. Based on region, the Global pneumonia vaccine market size is analyzed across North America, Europe, Asia-Pacific and LAMEA.
Based on vaccine type, the market is divided into pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine. The pneumococcal conjugate vaccine segment is largest contributor to the global pneumonia vaccine market in 2017 and is expected to maintain its dominant position throughout the analysis period. These vaccines can immunize the infants and children from 6 weeks to 5 years of age to prevent the invasive disease, pneumonia, and acute otitis media. The PCV vaccines segment is expected to hold the maximum market share owing to rise in adoption and usage of the vaccine amongst the population as many are susceptible to pneumonia, which includes children below 5 years and adults above 50 years. Thus, it contributes the largest share in the global pneumonia vaccines market. On the other side, pneumococcal polysaccharide vaccine segment is the fastest growing segment during the forecast period, owing to the Pneumovax 23 is proven efficacious against invasive pneumonia disease in healthy young adults. It is primarily indicated to use in population aged 50 year and above and population aged more than 2 years.
According to global pneumonia vaccine market analysis, the product type segment is classified into Prevnar 13, Synflorix, and Pneumovax 23. Throughout the forecast period, the Prevnar 13 segment is expected to be the fastest growing segment as it is most widely used pneumonia vaccine across the world; recommended by WHO due to its efficiency in pneumonia prevention. Moreover, Prevnar 13 is also used in adults aged more than 50 years for the prevention of pneumonia disease. Based on sector, the market is divided into two sector namely public and private sectors. The private sector is largest segment contributing to the global pneumonia vaccine market in 2017 and is expected to maintain its dominant position throughout the analysis period. This sector includes private hospitals, clinics, and others. The private hospitals sell vaccines for the treatment of pneumonia at a higher cost as compared to the non-profit organizations. According to global pneumonia vaccine market analysis, the distribution channel segment is segmented into distribution partner companies, non-governmental organizations (NGO) and government authorities. The non-governmental organizations segment is anticipated to be the largest segment due to organizations such as UNICEF, GAVI, charitable trusts, and WHO. They work to improve the healthcare worldwide and provide access of the life-saving medicines to the economically backward population. These organizations purchase pneumonia vaccines from the manufacturer and provide them directly to the destination geographies which predominantly fuels the growth of the global pneumonia vaccine market worldwide.
Send Enquiry on this report @ https://www.alliedmarketresearch.com/purchase-enquiry/2730